Scarica l'app Stockscreener
18.54
1.70%
0.31
Dopo l'orario di chiusura:
18.54
Mediwound Ltd Borsa (MDWD) Ultime notizie
MediWound (NASDAQ:MDWD) shareholder returns have been respectable, earning 53% in 5 years - Simply Wall St
MediWound (MDWD) Projected to Post Earnings on Wednesday - Defense World
MediWound Ltd. (NASDAQ:MDWD) Shares Acquired by Rhumbline Advisers - Defense World
Pollard Banknote Reports 4th Quarter and Annual Financial Results - The Globe and Mail
MediWound Ltd. to Host Earnings Call - ACCESS Newswire
MediWound at TD Cowen Conference: Strategic Insights on Growth - Investing.com India
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
When Will MediWound Reveal Its 2024 Financial Performance? Key Date Announced - StockTitan
MediWound (NASDAQ:MDWD) Research Coverage Started at Craig Hallum - Defense World
MediWound (NASDAQ:MDWD) Now Covered by Analysts at Craig Hallum - MarketBeat
Craig-Hallum sets $39 target on MediWound stock with buy rating - Investing.com Canada
(MDWD) Investment Report - Stock Traders Daily
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Craig-Hallum sets $39 target on MediWound stock with buy rating By Investing.com - Investing.com South Africa
Laurentian Bank of Canada declares dividend on its common shares - The Globe and Mail
Burns Pipeline 2024: Therapies, MOA Insights, and Key Clinical - openPR
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care - GlobeNewswire
Can NexoBrid Transform Pediatric Burn Care? Phase III Results Show Superiority - StockTitan
MediWound to Present at the 45th Annual TD Cowen Health Care Conference - GlobeNewswire
Can MediWound's Tissue Repair Innovation Reshape the Healthcare Market? CEO Reveals Strategy - StockTitan
(MDWD) Trading Signals - Stock Traders Daily
MediWound stock climbs 4% on Phase 3 study initiation - MSN
MediWound begins pivotal Phase III trial for wound therapy By Investing.com - Investing.com Nigeria
MediWound begins pivotal Phase III trial for wound therapy - MSN
MediWound Launches Phase III Trial Evaluating EscharEx for Treating Venous Leg Ulcers - Marketscreener.com
Mediwound’s EscharEx Shows Promising Results in Phase 3 Trial - TipRanks
MediWound Launches Phase III Trial for EscharEx Targeting Venous Leg Ulcers - TipRanks
MediWound to launch Phase III trial for venous leg ulcers -February 12, 2025 at 07:00 am EST - Marketscreener.com
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers - GlobeNewswire
EscharEx Clinical Trial: MediWound's Groundbreaking Solution for $375M Venous Ulcer Market - StockTitan
Is MediWound (NASDAQ:MDWD) In A Good Position To Invest In Growth? - Simply Wall St
JPMorgan Chase & Co. Has $61,000 Stock Position in MediWound Ltd. (NASDAQ:MDWD) - MarketBeat
How the (MDWD) price action is used to our Advantage - Stock Traders Daily
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times
Exclusive: MediWound CEO to Reveal Latest Tissue Repair Innovations at Major Healthcare Conference - StockTitan
JPMorgan Chase & Co. Sells 75,360 Shares of MediWound Ltd. (NASDAQ:MDWD) - Defense World
MediWound Ltd.'s (NASDAQ:MDWD) high institutional ownership speaks for itself as stock continues to impress, up 15% over last week - Yahoo Finance
MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains? - Yahoo Finance
Barclays PLC Increases Stock Holdings in MediWound Ltd. (NASDAQ:MDWD) - Defense World
BioHarvest Sciences Strengthens Board with Healthcare Industry Veteran Sharon Malka - StockTitan
Burns Pipeline 2024: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | MediWound, Kaken Pharma, Kerecis, Medline, Mallinckrodt Pharma, Avita Medical, Vericel Corp - The Globe and Mail
Trading (MDWD) With Integrated Risk Controls - Stock Traders Daily
HC Wainwright Reaffirms “Buy” Rating for MediWound (NASDAQ:MDWD) - Defense World
MediWound (NASDAQ:MDWD) Receives "Buy" Rating from HC Wainwright - MarketBeat
Mediwound Advances in Enzymatic Therapeutics with Strategic Expansions - Yahoo Finance
MediWound Ltd.'s (NASDAQ:MDWD) P/S Still Appears To Be Reasonable - Simply Wall St
Geode Capital Management LLC Sells 2,365 Shares of MediWound Ltd. (NASDAQ:MDWD) - Defense World
Barclays PLC Raises Stake in MediWound Ltd. (NASDAQ:MDWD) - Defense World
0.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):